Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Sponsor: Gynecologic Oncology Group
This PHASE2 trial investigates Ovarian Carcinoma and is currently completed. Gynecologic Oncology Group leads this study, which shows 12 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Feb 2021 — Dec 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Feb 2017 — Feb 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Allentown, United States, Amarillo, United States, Aurora, United States, Buffalo, United States, Burlington, United States, Charlotte, United States, Charlottesville, United States, Chicago, United States, Cincinnati, United States, Cleveland, United States and 39 more location s